Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tezacaftor

- PMLiVE

Orkambi buyers’ club set up to gain access to cheaper versions

Legal to import generics from abroad

- PMLiVE

Vertex makes choice for all-important CF triple therapy

Promises to treat up to 90% of CF patients

- PMLiVE

NHS England wants money-back guarantee on Orkambi

Vertex resisting real-world data proposal

The Orkambi row explained

Q&A and timeline

- PMLiVE

The Orkambi blame game

Grilling by MPs sheds some light on long-running row over CF drug

- PMLiVE

Setback for Vertex’s cystic fibrosis challenger Proteostasis

Unlikely to match market leader's triple therapy

- PMLiVE

Is Orkambi deal close? Vertex meets again today with NHS England

Campaigners hopes rise after three year wait

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

Hardy returns to Genentech as CEO

In other news, Vertex fires chief operating officer

- PMLiVE

Vertex gains EU approval for earlier Orkambi use

Cystic Fibrosis drug approved in children aged 2-5 years

- PMLiVE

Vertex rises on data for cystic fibrosis triple therapy

Company will wait for further results before filing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links